The trial is designed to assess the tolerability, efficacy, and safety of two different dosages of the therapy.

A case study published by researchers at Johns Hopkins University showed that optical genome mapping (OGM) detected a structural variant that was ...

By Karen Roman Oculis Holding AG (Nasdaq: OCS) said Phase 2 of its neuroprotective candidate OCS-05 met key endpoints of ...

Ozone therapy offers new hope for sepsis-induced lung injury by improving lung function and survival through enhanced ...

Sepsis, a severe and often fatal complication of infection, is a leading cause of both ALI and acute respiratory distress ...

As medicine continues to progress toward personalized medicine, targeted therapy methodologies show promise to improve ...

Venetoclax is under clinical development by AbbVie and currently in Phase II for Refractory Acute Myeloid Leukemia.

Introduction Acute exacerbation of interstitial lung disease (AE-ILD) often results in death and poses significant challenges ...

Sepsis, a severe and often fatal complication of infection, is a leading cause of both acute lung injury (ALI) and acute ...

Oculis Holding ( (OCS) ) has issued an update. Oculis Holding has announced positive results from a Phase 2 trial for OCS-05, a potential first-in-class neuroprotective therapy for acute optic ...

China's top drug regulator has recently approved the nation's first stem cell therapy to treat a type of complication ...